UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor Myrcludex B

Journal of hepatology, 2016-09, Vol.65 (3), p.483-489

2016

Volltextzugriff (PDF)

CYP3A activity: towards dose adaptation to the individual

Expert opinion on drug metabolism & toxicology, 2016-05, Vol.12 (5), p.479-497

2016

Volltextzugriff (PDF)

Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole

Clinical pharmacokinetics, 2016-12, Vol.55 (12), p.1535-1545

2016

Volltextzugriff (PDF)

Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects

Journal for immunotherapy of cancer, 2021-10, Vol.9 (10), p.e002505

2021

Volltextzugriff (PDF)

Dose‐dependent induction of CYP3A activity by St. John's wort alone and in combination with rifampin

Clinical and translational science, 2024-08, Vol.17 (8), p.e70007-n/a

2024

Volltextzugriff (PDF)

Estrogen Receptor Signaling and the PI3K/Akt Pathway Are Involved in Betulinic Acid-Induced eNOS Activation

Molecules (Basel, Switzerland), 2016-07, Vol.21 (8), p.973-973

2016

Volltextzugriff (PDF)

Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase‐Positive Non‐Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat

Clinical and translational science, 2021-03, Vol.14 (2), p.487-491

2021

Volltextzugriff (PDF)

Molecular, Viral and Clinical Features of Alcohol- and Non-Alcohol-Induced Liver Injury

Current issues in molecular biology, 2022-03, Vol.44 (3), p.1294-1315

2022

Volltextzugriff (PDF)

Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1′-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry

Analytical and bioanalytical chemistry, 2012-03, Vol.402 (7), p.2439-2450

2012

Volltextzugriff (PDF)

A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer

Oncoimmunology, 2018-04, Vol.7 (4), p.e1303584-e1303584

2018

Volltextzugriff (PDF)

Ultrasensitive quantification of the CYP2E1 probe chlorzoxazone and its main metabolite 6-hydroxychlorzoxazone in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry after chlorzoxazone microdosing

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2016-08, Vol.1027, p.207-213

2016

Volltextzugriff (PDF)

First‐in‐human, randomized, double‐blind, placebo‐controlled, dose escalation trial of the anti‐herpes simplex virus monoclonal antibody HDIT101 in healthy volunteers

Clinical and translational science, 2022-10, Vol.15 (10), p.2366-2377

2022

Volltextzugriff (PDF)

Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer

BMC cancer, 2012-08, Vol.12 (1), p.361-361, Article 361

2012

Volltextzugriff (PDF)

Effects and risks associated with novel psychoactive substances: mislabeling and sale as bath salts, spice, and research chemicals

Deutsches Ärzteblatt international, 2014-02, Vol.111 (9), p.139-147

2014

Volltextzugriff (PDF)

Midazolam microdose to determine systemic and pre‐systemic metabolic CYP3A activity in humans

British journal of clinical pharmacology, 2015-02, Vol.79 (2), p.278-285

2015

Volltextzugriff (PDF)

Use of Microdose Phenotyping to Individualise Dosing of Patients

Clinical pharmacokinetics, 2015-09, Vol.54 (9), p.893-900

2015

Volltextzugriff (PDF)

Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses

British journal of clinical pharmacology, 2019-10, Vol.85 (10), p.2310-2320

2019

Volltextzugriff (PDF)

The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma

Leukemia, 2019-12, Vol.33 (12), p.2924-2933

2019

Volltextzugriff (PDF)

Clomethiazole inhibits cytochrome P450 2E1 and improves alcoholic liver disease

Gut, 2022-04, Vol.71 (4), p.842-844

2022

Volltextzugriff (PDF)

No Increased Risk of Ketoconazole Toxicity in Drug-Drug Interaction Studies

Journal of clinical pharmacology, 2016-10, Vol.56 (10), p.1203-1211

2016

Volltextzugriff (PDF)

Effects and Risks Associated with Novel Psychoactive Substances

Deutsches Ärzteblatt international, 2014-02

2014

Volltextzugriff (PDF)

Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Clinical cancer research, 2021-10, Vol.27 (20), p.5546-5556

2021

Volltextzugriff (PDF)

Clementine juice has the potential for drug interactions – In vitro comparison with grapefruit and mandarin juice

European journal of pharmaceutical sciences, 2017-01, Vol.97, p.247-256

2017

Volltextzugriff (PDF)

Inhibition of cytochrome P-4502E1 by clomethiazole improves alcoholic liver disease in alcohol-dependent patients: a short-term, randomized, controlled clinical trial

Journal of hepatology, 2020-08, Vol.73, p.S178-S179

2020

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(46)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor Myrcludex B

CYP3A activity: towards dose adaptation to the individual

Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole

Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects

Dose‐dependent induction of CYP3A activity by St. John's wort alone and in combination with rifampin

Estrogen Receptor Signaling and the PI3K/Akt Pathway Are Involved in Betulinic Acid-Induced eNOS Activation

Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase‐Positive Non‐Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat

Molecular, Viral and Clinical Features of Alcohol- and Non-Alcohol-Induced Liver Injury

Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1′-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry

A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer

Ultrasensitive quantification of the CYP2E1 probe chlorzoxazone and its main metabolite 6-hydroxychlorzoxazone in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry after chlorzoxazone microdosing

First‐in‐human, randomized, double‐blind, placebo‐controlled, dose escalation trial of the anti‐herpes simplex virus monoclonal antibody HDIT101 in healthy volunteers

Protocol of the IntenSify‐Trial: An open‐label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab‐paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy

Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer

Effects and risks associated with novel psychoactive substances: mislabeling and sale as bath salts, spice, and research chemicals

Midazolam microdose to determine systemic and pre‐systemic metabolic CYP3A activity in humans

Use of Microdose Phenotyping to Individualise Dosing of Patients

Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses

The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma

Clomethiazole inhibits cytochrome P450 2E1 and improves alcoholic liver disease

No Increased Risk of Ketoconazole Toxicity in Drug-Drug Interaction Studies

Effects and Risks Associated with Novel Psychoactive Substances

Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Clementine juice has the potential for drug interactions – In vitro comparison with grapefruit and mandarin juice

Inhibition of cytochrome P-4502E1 by clomethiazole improves alcoholic liver disease in alcohol-dependent patients: a short-term, randomized, controlled clinical trial

Suchergebnisse filtern